Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2018

  • ID: 4482736
  • Report
  • 223 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • CTI BioPharma Corp
  • Imago BioSciences Inc
  • Italfarmaco SpA
  • MedImmune LLC
  • Merck & Co Inc
  • MORE
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2018, provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline landscape.

Post-Polycythemia Vera Myelofibrosis (PPV-MF) is a myeloproliferative blood cancer in which the bone marrow makes too many red blood cells. It may also result in the overproduction of white blood cells and platelets. Symptoms include heart attack, stroke, deep venous thrombosis, Headaches, lack of concentration and fatigue. The disease may be controlled by chemotherapy, transfusions, transplant and medications.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 13, 6 and 1 respectively.

Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • CTI BioPharma Corp
  • Imago BioSciences Inc
  • Italfarmaco SpA
  • MedImmune LLC
  • Merck & Co Inc
  • MORE
Introduction

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Overview

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Development

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Assessment

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Companies Involved in Therapeutics Development

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Drug Profiles

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by AbbVie Inc, H1 2018

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Celgene Corp, H1 2018

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by CTI BioPharma Corp, H1 2018

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Gilead Sciences Inc, H1 2018

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Imago BioSciences Inc, H1 2018

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Incyte Corp, H1 2018

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Italfarmaco SpA, H1 2018

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by JW Pharmaceutical Corp, H1 2018

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by MedImmune LLC, H1 2018

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by MEI Pharma Inc, H1 2018

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Merck & Co Inc, H1 2018

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Novartis AG, H1 2018

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by NS Pharma Inc, H1 2018

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Pfizer Inc, H1 2018

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Promedior Inc, H1 2018

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Rhizen Pharmaceuticals SA, H1 2018

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects, H1 2018

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Celgene Corp
  • CTI BioPharma Corp
  • Gilead Sciences Inc
  • Imago BioSciences Inc
  • Incyte Corp
  • Italfarmaco SpA
  • JW Pharmaceutical Corp
  • MedImmune LLC
  • MEI Pharma Inc
  • Merck & Co Inc
  • Novartis AG
  • NS Pharma Inc
  • Pfizer Inc
  • Promedior Inc
  • Rhizen Pharmaceuticals SA
  • Sun Pharma Advanced Research Company Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll